A new hypothesis suggests that continuous glucose monitors, traditionally used for diabetes, may reveal hidden post-meal glucose surges in healthy people, potentially transforming personalised cardiovascular prevention but remains unproven.
A new hypothesis from two Romanian cardiologists argues that continuous glucose monitors, or CGMs, should not be viewed solely as diabetes devices. Instead, they suggest the sensors may help identify hidden glucose surges in otherwise healthy people, potentially offering a more individualised way to think about cardiovascular prevention. The idea is provocative but unproven: the authors themselves describe it as a hypothesis rather than a tested clinical strategy.
Their case rests on a simple but important critique of standard screening. Conventional measures such as fasting glucose and HbA1c can look normal even when a person experiences sharp post-meal spikes. Research published in the Proceedings of the Nutrition Society has shown that responses to identical meals are highly repeatable within the same person, yet vary substantially between different people. An accompanying MDedge report said factors including the gut microbiome, meal timing, sleep and prior activity can all shape that response, which helps explain why one-size-fits-all diet advice often falls short.
The cardiologists go further, arguing that the problem may lie less in the average blood sugar level than in the swings themselves. They point to laboratory and mechanistic evidence suggesting that acute glucose rises, even within the non-diabetic range, may trigger oxidative stress, reduce nitric oxide and activate inflammatory pathways in blood vessels. On that reading, a person with a “normal” fasting test could still be exposed to biologically meaningful damage after meals, while a CGM would be able to detect those spikes in real time.
From there, the proposal expands into a staged prevention framework: a baseline period of CGM use, followed by diet changes tailored to the wearer’s response, then fasting-based interventions, and finally, for selected higher-risk patients under medical supervision, consideration of off-label drugs such as metformin or acarbose. The broader message is not that everyone should start using a CGM, but that the device may be a useful teaching tool for a few weeks. As the authors acknowledge, it is not yet a validated risk test for healthy people.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
